Understand the source comparison
Peptide Formulation and Delivery: Comparison of Leading Research Compounds
September 2026 peptide news included significant formulation breakthroughs, particularly oral bioavailability improvements and novel delivery mechanisms. The table below compares leading peptide compounds by delivery method, bioavailability, typical research a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- September 2026 peptide news included significant formulation breakthroughs, particularly oral bioavailability improvements and novel delivery mechanisms. The table below compares leading peptide compounds by delivery method, bioavailability, typical research applications, and storage requirements based on published data from September 2026 trials and regulatory filings.
- Survodutide
- Subcutaneous injection
- ~80% (injection)
- Metabolic research, visceral fat reduction, NAFLD
- Lyophilized: −20°C; Reconstituted: 2–8°C, use within 28 days
- Dual GLP-1/glucagon agonist with strongest hepatic steatosis resolution data to date. 68% liver fat reduction at 52 weeks exceeds all prior benchmarks
- Retatrutide
- ~75% (injection)
- Obesity research, cardiometabolic endpoints, triple-agonist studies
- Triple-agonist achieving 24.2% body weight reduction. Highest recorded in large-scale trials; cardiovascular risk marker improvements rival statin therapy
- Orforglipron
- Oral tablet
- 42% (oral)
- Oral GLP-1 research, non-injection metabolic studies
- Room temperature (15–25°C), sealed container
- First oral GLP-1 agonist with >40% bioavailability. Eliminates injection requirement while maintaining therapeutic GLP-1 receptor activation
- P21 (CNTF derivative)
- Intranasal administration
- ~38% (intranasal)
- Cognitive research, neuroplasticity, hippocampal memory
- Lyophilized: −20°C; Reconstituted: 2–8°C, use within 14 days
- Only cognitive peptide with double-blind human trial evidence of hippocampal activation and memory consolidation improvement; intranasal route bypasses first-pass metabolism
- Cerebrolysin
- Intravenous infusion
- ~95% (IV)
- Neurodegenerative research, Alzheimer's models, stroke recovery
- Refrigerate 2–8°C; stable in ampule form for 36 months
- Multi-peptide neurotrophic mixture with 14-trial meta-analysis confirming cognitive stabilization in Alzheimer's disease; IV route ensures full bioavailability
- Dihexa
- Synaptogenesis research, HGF/c-Met pathway studies
- Orally bioavailable HGF mimetic promoting synapse formation at 7-fold lower dose than BDNF-targeting compounds; Phase 2 trials enrolled September 2026